PhocusWright Conference Honors Magicstay.Com With Launch People's Choice Award
26.11.2019 16:28:00 EET | Business Wire | Press release
On Thursday, November 21, MagicStay won the Launch People's Choice Award at the Phocuswright Conference in Fort Lauderdale, Florida - the world's leading event showcasing the latest technological trends in tourism.
This prestigious award, a veritable acknowledgement of the entire tourism and mobility sector, is a reflection of MagicStay's development strategy, which was put into effect over the past two years on a global scale. With this award, MagicStay has established itself as a key player in Business Travel and mobility on the international stage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005486/en/
A special prize for a special team! #MagicTeam (Photo: Business Wire)
MagicStay, winner of the Launch People's Choice Award
The Launch People's Choice Award recognizes companies which are at least 4 years old and have come up with an innovation that revolutionizes the travel industry. Through this award, the Phocuswright Conference showcases the latest trends and technological innovations in the main sectors of the travel market every year.
In a 10-minute pitch, William Lecerf, co-founder of MagicStay, was able to impress the Dragons - the ten members of the Jury. He received nine positive endorsements in front of around 2,000 of the most influential international experts from the travel industry. The prize was presented to William Lecerf, co-founder (on the left), Valéry Linyer, co-founder and CEO (in the center) and Slobodan Petrovic, COO (on the right).
These 2,000 experts then elected MagicStay.com ahead of twelve competitors previously selected by Phocuswright: Affirm, Airdna, Amadeus, Arrivalist, Cover Genius, HotelRunner, Left Travel, Mistifly, Nezasa, Sift, Kiwi or Travelcompsitor. The prize was awarded jointly to MagicStay.com and Kiwi.
The Dragons' comments were very complimentary:
"You are building a database which offers unique value that no-one else has managed to develop".
Will Philippson,
former Co-founder and COO SilveRail Technologies
"I really like the fact that your content is available in the SBTs".
Charuta Fadnis,
Senior Director Product Strategy and Analytics BCD Travel
"As an expat looking for accommodation in a foreign country, anything you can do to simplify this process is absolutely fantastic. It's an infernal procedure that companies spend a lot of time dealing with and your solution is BRILLANT".
Philip Wolf,
Serial Board Director and Founder Phocuswright Inc.
"I was really impressed by your Duty of Care presentation. As a large company, I know that this issue is one of the biggest fears we have to face when sending our employees abroad on assignments".
Gayle Knolls,
Head of Business Development TRAVELPORT
An effective development strategy
Launched in 2013 in Grasse, the www.MagicStay.com platform devoted its first five years of business to R&D.
After initially focusing on the market of trade show organizers, since 2016 MagicStay has been offering business travelers and, since the beginning of this year, expatriates and/or persons on professional mobility assignments, a secure alternative to professional hotels by responding to duty of care challenges, traveler safety demands and personal data protection, required by large companies.
While broadening its scope, the hosting platform dedicated to professionals has doubled its offer since the beginning of the year. It now has more than 600,000 apartments, villas or apart-hotels available throughout the world (in more than 3,000 cities and 130 countries).
In 2020, MagicStay hopes to reach one million hosting units.
The photo on the previous page and other photos are available on request
MagicStay media library (press releases, logo, photo gallery, etc.)
Join us on: Facebook Twitter LinkedIn
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005486/en/
Contact information
MagicStay press contacts:
Fabienne Frédal (AB3C)
Tel. +33 (0)1 53 30 74 07 - fabienne@ab3c.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom